Table 1 Summary of the number of screening participants and examinations, for cancer-diagnosed cases and healthy controls, for the entire dataset and relevant subgroups

From: Simulating mismatch between calibration and target population in AI for mammography the retrospective VAIB study

Group

Subgroup

Case-Control

Cohort

Participants

Exams

Participants

Exams

Case

Control

Case

Control

Case

Control

Case

Control

Overall

Overall

6028

27,422

7790

38,509

864

39,986

867

40,022

Image acquisition (equipment manufacturer)

GE

3692 (61.3%)

19,868 (80.6%)

5049 (65%)

30,730 (80%)

491 (57.2%)

20,598 (53.1%)

493 (57.3%)

20,369 (51.9%)

Philips

2327 (38.7%)

4776 (19.4%)

2723 (35%)

7663 (20%)

367 (42.8%)

18,166 (46.9%)

368 (42.7%)

18,868 (48.1%)

Population characteristics: Age

40–49

1037 (16.5%)

8386 (28.6%)

1257 (16.1%)

9362 (24.3%)

146 (16.9%)

11,702 (29.3%)

147 (17%)

11,706 (29.2%)

50–69

3885 (61.7%)

16,747 (57.2%)

4886 (62.5%)

23,540 (61.1%)

536 (62%)

21,884 (54.7%)

538 (62%)

21,908 (54.7%)

70+ 

1371 (21.8%)

4159 (14.2%)

1677 (21.4%)

5608 (14.6%)

182 (21.1%)

6404 (16%)

182 (21%)

6415 (16.1%)

Pre-menopausea

1826 (30%)

13,241 (47%)

2257 (29%)

15,393 (40%)

261 (30%)

18,642 (44.6%)

261 (30%)

18,650 (46.6%)

Post-menopauseb

4277 (70%)

14,834 (53%)

5495 (71%)

23,058 (60%)

603 (70%)

21,344 (55.4%)

603 (70%)

21,372 (53.4%)

Population characteristics: Mammographic densityc

A

582 (9.3%)

4139 (14.6%)

677 (7.9%)

5478 (14.2%)

88 (10.2%)

5700 (14.3%)

88 (9.6%)

5700 (14.2%)

B

3313 (52.6%)

14,958 (52.8%)

4187 (48.6%)

20,568 (53.4%)

450 (52%)

20,570 (51.4%)

499 (54.5%)

20,591 (51.4%)

C

2219 (35.3%)

9038 (31.9%)

2732 (31.7%)

11207 (29.1%)

305 (35.3%)

12,613 (31.5%)

307 (33.5%)

12,621 (31.6%)

D

176 (2.8%)

194 (0.7%)

1013 (11.8%)

1259 (3.3%)

22 (2.5%)

1117 (2.8%)

22 (2.4%)

1119 (2.8%)

Cancer characteristics

Invasive

4990 (86.7%)

NA

6462 (86.7%)

NA

708 (85.3%)

NA

710 (85.3%)

NA

In situ

768 (13.3%)

NA

995 (13.3%)

NA

122 (14.7%)

NA

122 (14.7%)

NA

  1. aPre-menopause is defined as screening participants less than or equal to 55 years of age.
  2. bPost-menopause is defined as screening participants more than 55 years of age.
  3. cDensity categories were assigned by the Lunit INSIGHT MMG system (South Korea, v.1.1.7.2).
Back to article page